Telomere length and Parkinson's disease in men: A nested case-control study

European Journal of Neurology

Volumn 21, Issue 1, 2014, Pages 93-99

  Schurks M ^a,b   Buring, J ^a   Dushkes, R ^a   Gaziano, J M ^a   Zee, R Y L ^a,c   Kurth, T ^a,d,e  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c TUFTS UNIVERSITY SCHOOL OF DENTAL MEDICINE   (United States)

^d INSERM   (France)

^e UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Epidemiology; Nested case control study; Parkinson's disease; Telomere length

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; GENOMIC DNA; LEVODOPA;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; GENE DOSAGE; HUMAN; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK; SELF REPORT; TELOMERE; TELOMERE SHORTENING;

EPIDEMIOLOGY; NESTED CASE-CONTROL STUDY; PARKINSON'S DISEASE; TELOMERE LENGTH;

AGED; CASE-CONTROL STUDIES; HUMANS; MALE; PARKINSON DISEASE; POLYMERASE CHAIN REACTION; TELOMERE;

EID: 84890123153     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12252     Document Type: Article

References (26)

1. Blackburn EH. Telomeres and telomerase: their mechanisms of action and the effects of altering their functions. FEBS Lett 2005; 579: 859-862.
2. Blasco MA. Telomeres and human disease: ageing, cancer and beyond. Nat Rev Genet 2005; 6: 611-622.
3. Alves G, Forsaa EB, Pedersen KF, Dreetz Gjerstad M, Larsen JP. Epidemiology of Parkinson's disease. J Neurol 2008; 255(Suppl. 5): 18-32.
4. Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol 2009; 8: 382-397.
5. Lees AJ, Hardy J, Revesz T. Parkinson's disease. Lancet 2009; 373: 2055-2066.
6. Kume K, Kikukawa M, Hanyu H, et al. Telomere length shortening in patients with dementia with Lewy bodies. Eur J Neurol 2012; 19: 905-910.
7. Panossian LA, Porter VR, Valenzuela HF, et al. Telomere shortening in T cells correlates with Alzheimer's disease status. Neurobiol Aging 2003; 24: 77-84.
8. Guan JZ, Maeda T, Sugano M, et al. A percentage analysis of the telomere length in Parkinson's disease patients. J Gerontol A Biol Sci Med Sci 2008; 63: 467-473.
9. Eerola J, Kananen L, Manninen K, Hellstrom O, Tienari PJ, Hovatta I. No evidence for shorter leukocyte telomere length in Parkinson's disease patients. J Gerontol A Biol Sci Med Sci 2010; 65: 1181-1184.
10. Hudson G, Faini D, Stutt A, et al. No evidence of substantia nigra telomere shortening in Parkinson's disease. Neurobiol Aging 2011; 32: 2107.e3-2107.e5.
11. Wang H, Chen H, Gao X, et al. Telomere length and risk of Parkinson's disease. Mov Disord 2008; 23: 302-305.
12. Watfa G, Dragonas C, Brosche T, et al. Study of telomere length and different markers of oxidative stress in patients with Parkinson's disease. J Nutr Health Aging 2011; 15: 277-281.
13. Anonymous. Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med 1989; 321: 129-135.
14. Hennekens CH, Buring JE, Manson JE, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996; 334: 1145-1149.
15. Driver JA, Logroscino G, Buring JE, Gaziano JM, Kurth T. A prospective cohort study of cancer incidence following the diagnosis of Parkinson's disease. Cancer Epidemiol Biomarkers Prev 2007; 16: 1260-1265.
16. Driver JA, Kurth T, Buring JE, Gaziano JM, Logroscino G. Parkinson disease and risk of mortality: a prospective comorbidity-matched cohort study. Neurology 2008; 70: 1423-1430.
17. Zee RY, Michaud SE, Germer S, Ridker PM. Association of shorter mean telomere length with risk of incident myocardial infarction: a prospective, nested case-control approach. Clin Chim Acta 2009; 403: 139-141.
18. Cawthon RM. Telomere measurement by quantitative PCR. Nucleic Acids Res 2002; 30: e47.
19. Zee RY, Castonguay AJ, Barton NS, Buring JE. Mean telomere length and risk of incident colorectal carcinoma: a prospective, nested case-control approach. Cancer Epidemiol Biomarkers Prev 2009; 18: 2280-2282.
20. Zee RY, Michaud SE, Ridker PM. Mean telomere length and risk of incident venous thromboembolism: a prospective, nested case-control approach. Clin Chim Acta 2009; 406: 148-150.
21. Barnham KJ, Masters CL, Bush AI. Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov 2004; 3: 205-214.
22. Mirabello L, Huang WY, Wong JY, et al. The association between leukocyte telomere length and cigarette smoking, dietary and physical variables, and risk of prostate cancer. Aging Cell 2009; 8: 405-413.
23. Chen H, Huang X, Guo X, et al. Smoking duration, intensity, and risk of Parkinson disease. Neurology 2010; 74: 878-884.
24. Kipling D. Telomeres, replicative senescence and human ageing. Maturitas 2001; 38: 25-37.
25. Njajou OT, Hsueh WC, Blackburn EH, et al. Association between telomere length, specific causes of death, and years of healthy life in health, aging, and body composition, a population-based cohort study. J Gerontol A Biol Sci Med Sci 2009; 64: 860-864.
26. Bekaert S, De Meyer T, Rietzschel ER, et al. Telomere length and cardiovascular risk factors in a middle-aged population free of overt cardiovascular disease. Aging Cell 2007; 6: 639-647.